Cargando…
V2 Receptor Antagonist; Tolvaptan
Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases. Although knowledge of hyponatremia has been cumulated,...
Autores principales: | Yi, Joo-Hark, Shin, Hyun-Jong, Kim, Ho-Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Electrolyte Metabolism
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302906/ https://www.ncbi.nlm.nih.gov/pubmed/22438856 http://dx.doi.org/10.5049/EBP.2011.9.2.50 |
Ejemplares similares
-
Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V(2)-Receptor Antagonist Tolvaptan
por: Gaglio, Paul, et al.
Publicado: (2012) -
The V(2) receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells
por: Marroncini, G., et al.
Publicado: (2022) -
Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone
por: Han, Sang Woong, et al.
Publicado: (2018) -
Evidence for Effective Multiple K(+)-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V(2) Receptor
por: Lu, Te-Ling, et al.
Publicado: (2019) -
Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)